Volume 4, Issue 4 (10-2019)                   CJHR 2019, 4(4): 86-89 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Andalib S, Ghayeghran A, Moadabi Y, Asadi K, Mohammadpour M, Ghorbani-Shirkouhi S. Association of Diabetes Mellitus Type 2 and Alzheimer's Disease. CJHR 2019; 4 (4) :86-89
URL: http://cjhr.gums.ac.ir/article-1-135-en.html
1- Neuroscience Research Center, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran , andalib@gums.ac.ir
2- Department of Neurology, Poursina Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
3- Orthopaedic Research Center, Department of Orthopaedic Surgery, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran
4- Neuroscience Research Center, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran
Abstract:   (2018 Views)
Background: Insulin serves an important role in brain metabolism, and insulin resistance and subsequent diabetes mellitus type 2 (DM2) can give rise to dysfunction of brain metabolism. This study aimed to test the hypothesis of association of late onset Alzheimer's disease (AD) with DM2 in an Iranian population.
Methods: In this case-control study, 243 subjects including 81 patients with late onset AD and 162 healthy controls were recruited. The frequency of DM were compared in AD patients with non-AD counterparts.
Results: The prevalence of diabetes in AD and control patients was 27% and 9%, respectively. (OR = 3.94, 95% confidence interval: 1.89-8.22). After adjustment for age and gender, there was a significant association between DM2 and AD (OR = 3.7, 95% confidence interval: 1.73-8.00).
Conclusion: The evidence from the present study suggested that DM2 was associated with AD in an Iranian population. Further longitudinal studies are warranted to confirm this finding.
 
Full-Text [PDF 528 kb]   (583 Downloads)    
Article Type: Original Contributions | Subject: Epidemiology
Received: 2019/07/27 | Accepted: 2019/09/18 | Published: 2019/10/1

References
1. Burns A, Iliffe S. Alzheimer's disease. BMJ. 2009;338:b158. doi: 10.1136/bmj.b158. [DOI:10.1136/bmj.b158]
2. Mehdizadeh E, Khalaj-Kondori M, Shaghaghi-Tarakdari Z, Sadigh-Eteghad S, Talebi M, Andalib S. Association of MS4A6A, CD33 and TREM2 gene polymorphisms with the late onset Alzheimer's disease. Bioimpacts. 2019;9(4):219-225. Doi: 10.15171/bi.2019.27
3. Andalib S, Divani AA, Michel TM, Høilund-Carlsen PF, Vafaee MS, Gjedde A. Pandora's Box: mitochondrial defects in ischaemic heart disease and stroke. Expert Rev Mol Med. 2017;19:e5. doi: 10.1017/erm.2017.5. [DOI:10.1017/erm.2017.5]
4. Jalbert JJ, Daiello LA, Lapane KL. Dementia of the Alzheimer type. Epidemiol Rev. 2008;30:15-34. doi: 10.1093/epirev/mxn008. [DOI:10.1093/epirev/mxn008]
5. de la Monte SM. Type 3 diabetes is sporadic Alzheimers disease: mini-review. Eur Neuropsychopharmacol. 2014;24(12):1954-1960. doi: 10.1016/j.euroneuro.2014.06.008. [DOI:10.1016/j.euroneuro.2014.06.008]
6. van Cauwenberghe C, van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421-430. doi: 10.1038/gim.2015.117. [DOI:10.1038/gim.2015.117]
7. Motavallian A, Andalib S, Vaseghi G, Mirmohammad-Sadeghi H, Amini M. Association between PRO12ALA polymorphism of the PPAR-gamma2 gene and type 2 diabetes mellitus in Iranian patients. Indian J Hum Genet. 2013;19(2):239-244. doi: 10.4103/0971-6866.116126. [DOI:10.4103/0971-6866.116126]
8. Andalib S, Vaseghi G, Motavallian A, Sadeghi HM, Eshraghi A, Amini M, et al. Association of polymorphism of ser311cys paraoxonase-2 gene with type 2 diabetes mellitus in iran. Int J Prev Med. 2013;4(5):517-522.
9. de la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol. 2014;88(4):548-559. doi: 10.1016/j.bcp.2013.12.012. [DOI:10.1016/j.bcp.2013.12.012]
10. Peila R, Rodriguez BL, Launer LJ; Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002;51(4):1256-1262. doi: 10.2337/diabetes.51.4.1256. [DOI:10.2337/diabetes.51.4.1256]
11. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61(5):661-666. doi: 10.1001/archneur.61.5.661. [DOI:10.1001/archneur.61.5.661]
12. Hassing LB, Johansson B, Nilsson SE, Berg S, Pedersen NL, Gatz M, et al. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr. 2002;14(3):239-248. doi: 10.1017/S104161020200844X. [DOI:10.1017/S104161020200844X]
13. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269. doi: 10.1016/j.jalz.2011.03.005. [DOI:10.1016/j.jalz.2011.03.005]
14. Fukazawa R, Hanyu H, Sato T, Shimizu S, Koyama S, Kanetaka H, et al. Subgroups of Alzheimer's disease associated with diabetes mellitus based on brain imaging. Dement Geriatr Cogn Disord. 2013;35(5-6):280-290. doi: 10.1159/000348407. [DOI:10.1159/000348407]
15. Kopf D, Frolich L. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis. 2009;16(4):677-685. doi: 10.3233/jad-2009-1011. [DOI:10.3233/JAD-2009-1011]
16. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53(2):474-481. doi: 10.2337/diabetes.53.2.474. [DOI:10.2337/diabetes.53.2.474]
17. Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol. 2006;63(11):1551-1555. doi: 10.1001/archneur.63.11.1551. [DOI:10.1001/archneur.63.11.1551]
18. Al-Emam A, Elhaddad AA, Ramadan E. The risk of clinically diagnosed Alzheimer disease in patients with non insulin dependent diabetes mellitus. Egypt J Neurol Neurosurg Psychiatr. 2010;47(1):419-424.
19. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord. 2002;14(2):77-83. doi: 10.1159/000064928. [DOI:10.1159/000064928]
20. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology. 2004;63(7):1181-1186. doi: 10.1212/01.wnl.0000140291.86406.d1. [DOI:10.1212/01.WNL.0000140291.86406.D1]
21. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology. 2010;75(13):1195-1202. doi: 10.1212/WNL.0b013e3181f4d7f8. [DOI:10.1212/WNL.0b013e3181f4d7f8]
22. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, et al. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology. 2011;77(12):1126-1134. doi: 10.1212/WNL.0b013e31822f0435. [DOI:10.1212/WNL.0b013e31822f0435]
23. Wang KC, Woung LC, Tsai MT, Liu CC, Su YH, Li CY. Risk of Alzheimer's disease in relation to diabetes: a population-based cohort study. Neuroepidemiology. 2012;38(4):237-244. doi: 10.1159/000337428. [DOI:10.1159/000337428]
24. de la Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs. 2009;10(10):1049-1060.
25. de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs. 2012;72(1):49-66. doi: 10.2165/11597760-000000000-00000. [DOI:10.2165/11597760-000000000-00000]
26. de la Monte SM. Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimers Dis. 2012;30(Suppl 2):S231-249. doi: 10.3233/jad-2012-111727. [DOI:10.3233/JAD-2012-111727]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Caspian Journal of Health Research

Designed & Developed by : Yektaweb